Icotrokinra Psoriasis Trial Shows Durable Response
ADULTS with moderate-to-severe plaque psoriasis treated with the oral interleukin-23 (IL-23) receptor inhibitor icotrokinra maintained high rates of skin clearance and symptom improvement through 52…